As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term effects must be carefully monitored.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often sold as Zepbound, and semaglutide, often sold as Wegovy, over.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management. Approved by CDSCO, it targets G

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to more than $1 billion in new costs this year.

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That's left many patients wondering what to do next.